Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma

Yotaro Motomura; Yoshihiro Umezawa; Tomoyuki Arimatsu; Keigo Okada; Osamu Miura; Takashi Kumagai

doi:10.1002/ccr3.5372

Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma

Clin Case Rep. 2022 Feb 9;10(2):e05372. doi: 10.1002/ccr3.5372. eCollection 2022 Feb.

Authors

Yotaro Motomura¹, Yoshihiro Umezawa², Tomoyuki Arimatsu¹, Keigo Okada¹, Osamu Miura², Takashi Kumagai¹

Affiliations

¹ Department of Hematology Ome Municipal General Hospital Tokyo Japan.
² Department of Hematology Tokyo Medical and Dental University Tokyo Japan.

Abstract

We report a case of fever of unknown origin in a patient with MDS associated with IgM-MGUS. The patient was positive for MYD88 mutation, and chemotherapy for LPL/WM improved the fever. Analysis of MYD88 and the effect of chemotherapy on LPL/WM finally revealed the latent LPL/WM in this case.

Keywords: Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia; myelodysplastic syndrome; myeloid differentiation primary response 88.

Publication types

Case Reports